Active Biotech Interim Report January – June 2020


Second quarter in brief

  • Dr Elaine Sullivan, Dr Aleksandar Danilovski and Dr Axel Glasmacher were appointed as new members of the Board at the Annual General Meeting on May 19
  • Active Biotech provided status update in the portfolio projects
  • New preclinical data on tasquinimod’s effects in experimental models for multiple myeloma were presented at the Virtual Edition of the 25th European Hematology Association Annual Congress Meeting in June

Events after the end of the period
            ·First patient dosed in the phase 1b/2a study of tasquinimod use in treatment of multiple myeloma

Financial summary

SEK M Q2 Q1-Q2 Full-year
  2020 2019 2020 2019 2019
Net sales 1.1 0.5 6.6 8.4
Operating loss -10.1 -5.4 -19.9 -11.8 -32.3
Loss after tax -9.8 -5.5 -19.9 -13. (Read more…)6 -34.1
Earnings per share (SEK) -0.07 -0.04 -0.14 -0.09 -0.24
Cash and cash equivalents (at close of period)     38.2 77.2 59.7

For further information, please contact:

  Helén Tuvesson, CEO
  Tel: +46 (0)46-19 21 56


  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00

The report is also available at www.activebiotech.com.

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. This information was provided to the media, through the agency of the contact person set out above, for publication on August 6, 2020 at 8:30 a.m. CEST.



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.